What records are connected here?
- Evidence lanes
- 3
- Source years
- 9
- Drugs@FDA applications
- 1
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Smaller human trialsHormones · Sexual and reproductive health
Nafarelin is a lab-made ten-amino-acid analogue of gonadotropin-releasing hormone (GnRH) and the active ingredient in Synarel.1,2 Its U.S. label covers central precocious puberty in children and endometriosis in women 18 and older, for whom experience is limited to six months of treatment.1 In controlled studies described in the label, it relieved endometriosis symptoms about as well as danazol or leuprolide, but bone density fell during six months of treatment and recovered only partly.1
| What it is | A synthetic decapeptide analogue of gonadotropin-releasing hormone that, used repeatedly, lowers the body’s production of sex hormones, according to the Synarel label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Synarel, NDA 019886, with an original approval date of February 13, 1990. The cited label has no boxed warning.1,2 |
| Human evidence | Controlled studies in endometriosis comparing it with danazol and with leuprolide, and clinical trials in children with central precocious puberty, described in the label.1 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Nafarelin is a synthetic peptide of ten amino acids, an analogue of the natural gonadotropin-releasing hormone in which one amino acid is replaced by 3-(2-naphthyl)-D-alanine, according to the label.1
In the United States it is the active ingredient of Synarel, approved under NDA 019886, according to Drugs@FDA.2
The label states that nafarelin first stimulates the pituitary to release LH and FSH, briefly raising sex hormone production, and that repeated use then abolishes this stimulation, so tissues that depend on sex hormones become inactive.1
In controlled clinical studies in endometriosis, the label states that nafarelin was comparable to danazol in relieving pelvic pain, painful periods and painful intercourse and in shrinking endometrial implants, and a single controlled trial found it clinically comparable to leuprolide.1
After six months of treatment, vertebral bone density measured by CT fell by an average of 8.7%, with only partial recovery after treatment stopped, according to the label.1
In clinical trials in children with central precocious puberty, breast development stopped or regressed in 82% of girls and genital development in all boys, and the effects reversed in all 69 children with a year of follow-up after treatment, according to the label.1
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Yes. Drugs@FDA lists Synarel, application NDA 019886, with an original approval date of February 13, 1990.2
The Synarel label cited here (DailyMed SPL version 23, published March 10, 2026) states that it is indicated for central precocious puberty in children of both sexes and for the management of endometriosis, and that experience in endometriosis is limited to women 18 and older treated for six months.1
The label has no boxed warning. It states that it must not be used in pregnancy, and it warns that depression may occur or worsen with GnRH agonists.1
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Nafarelin is not among them.3,4
The clinical meaning of smaller endometriosis lesions: the label states that it is not known, and that lesion staging does not necessarily match symptom severity.1
Its use in endometriosis beyond six months, which the label states experience does not cover.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Nafarelin: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Nafarelin are a bounded selection, not every registration or paper about Nafarelin. For the years before Nafarelin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Nafarelin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Nafarelin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Synarel for central precocious puberty and endometriosis. Controlled studies described in the label found it comparable to danazol and leuprolide for endometriosis symptoms. Bone density fell during six months of treatment and recovered only partly.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Synarel for central precocious puberty and endometriosis. Controlled studies described in the label found it comparable to danazol and leuprolide for endometriosis symptoms. Bone density fell during six months of treatment and recovered only partly.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date November 9, 2026
An attempt to alter the pathophysiology of polycystic ovary syndrome using a gonadotrophin hormone releasing hormone agonist--Nafarelin.↗Added to PeptideScanner November 16, 2026Literature metadata · added November 16, 2026
An attempt to alter the pathophysiology of polycystic ovary syndrome using a gonadotrophin hormone releasing hormone agonist--Nafarelin.↗Source date November 9, 2026Literature metadata · added November 16, 2026
A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone.↗Source date November 2, 2019Literature metadata · added November 16, 2026
A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol.↗Source date August 28, 2019PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
2 of 2 selected trial records include at least one phase value; 2 of 2 include a status value in the retained structured contract.
25 of 25 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00034047 at 2026-11-16T01:35:57.709Z. Its registry update date was 2008-01-25, and PeptideScanner's reviewed identity mapping was nafarelin.
PeptideScanner retained ClinicalTrials.gov record NCT02865681 at 2026-11-16T01:35:57.709Z. Its registry update date was 2019-03-19, and PeptideScanner's reviewed identity mapping was nafarelin.
The official Drugs@FDA dataset lists original submission 1 for NDA 019886 with status AP dated 1990-02-13, and names nafarelin acetate among the application record's active ingredients.
25 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
Selected records span February 13, 1990 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 2533526 in Clinical endocrinology as Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1989-09 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 9209899 in Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1997-06 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 1834049 in The Australian & New Zealand journal of obstetrics & gynaecology as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1991-05 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 8860440 in Pharmaceutical research as Journal Article, Research Support, U.S. Gov't, P.H.S., with publication-date metadata of 1996-05 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 9720832 in European journal of obstetrics, gynecology, and reproductive biology as Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-08 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 1533376 in Fertility and sterility as Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1992-05 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 2140996 in Fertility and sterility as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1990-06 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 9389816 in Fertility and sterility as Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1997-11 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 1531576 in American journal of obstetrics and gynecology as Comparative Study, Journal Article, Review, with publication-date metadata of 1992-02 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 2137972 in American journal of obstetrics and gynecology as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1990-02 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 2137975 in American journal of obstetrics and gynecology as Comparative Study, Journal Article, Review, with publication-date metadata of 1990-02 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 2137976 in American journal of obstetrics and gynecology as Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, with publication-date metadata of 1990-02 (month precision). PeptideScanner associated the retained record with the identity slug nafarelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026